Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab.
about
Management of moderate to severe psoriasis in patients with metabolic comorbiditiesConsiderations for Systemic Treatment of Psoriasis in Obese Patients.Association of Adipokines, Insulin Resistance, Hypertension and Dyslipidemia in Patients with Psoriasis VulgarisStudy on Certain Biomarkers of Inflammation in Psoriasis Through "OMICS" Platforms.C-reactive protein in psoriasis: a review of the literature.Does treatment of psoriasis reduce the risk of cardiovascular disease?Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction.The triad psoriasis-obesity-adipokine profile.Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity.Adipokines in psoriasis: An important link between skin inflammation and metabolic alterations.Lessons to be learned from serum biomarkers in psoriasis and IBD - the potential role in SpA.Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma.Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI.Changes in circulating cell-free DNA and nucleosomes in patients with exacerbated psoriasis.Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics.Increased serum chemerin level to predict early onset of aortic valve stenosis.Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis.Relationship between plasma chemerin levels and disease severity in COPD patients.Diet and physical exercise in psoriasis: a randomized controlled trial
P2860
Q28087039-761D1D78-24C0-4465-AA91-EE3068E30F6EQ30249013-0C400A62-8055-4CDB-999F-21C6364436C1Q36534602-4626976B-B033-4346-BF03-2A25774F0BA0Q37673703-0EB42C58-00A3-447B-8ECF-2CAFE9DA51DCQ38133614-3D195F17-0BEF-4E5C-B19B-3C3A9AB4009AQ38178202-95B7CA74-5D70-4632-BBA0-4AEACC6EB99AQ38649854-88B0ABDC-027C-4B1F-B6F1-AD1F5BDA82A3Q38845553-57AACEE7-556B-45F2-A328-5C2721307510Q38870692-D3E39834-D840-4875-9284-74602B837E8BQ38935290-CC9A3F41-6F0D-452C-8379-90AA09509E8BQ38972679-C8FBF8E0-36BC-4853-BD26-E9B951C14909Q41010316-4C56BBC7-E2FB-435A-9398-8BA20AAFF8F6Q43801124-7291813E-20AA-4A12-B9D2-02DD0E0562D2Q47658770-E7D8B516-55CD-4436-A743-5973C5743CEAQ47930789-0D4494D9-B198-4BE7-A9A3-B55687880647Q48508496-277ED283-5AEE-49F6-A7A2-43D67C590B40Q49249983-E6AE0F48-CF64-43EB-AAE7-22920B1FA77DQ51321920-E5950D1C-B3D8-4165-866C-D95679357DCAQ57244406-15A26B2D-ED1E-45B5-A2C0-F66650AC1D36
P2860
Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Serum chemerin is increased in ...... ing treatment with infliximab.
@en
Serum chemerin is increased in ...... ing treatment with infliximab.
@nl
type
label
Serum chemerin is increased in ...... ing treatment with infliximab.
@en
Serum chemerin is increased in ...... ing treatment with infliximab.
@nl
prefLabel
Serum chemerin is increased in ...... ing treatment with infliximab.
@en
Serum chemerin is increased in ...... ing treatment with infliximab.
@nl
P2093
P2860
P356
P1476
Serum chemerin is increased in ...... ing treatment with infliximab.
@en
P2093
P2860
P304
P356
10.1111/BJD.12118
P407
P577
2013-02-27T00:00:00Z